Kodu・Aktsiate loetelu・ADMA Biologics Inc

ADMA Biologics Inc

Suletud

SektorTervishoid

8.26 -1.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.17

Max

8.39

Põhinäitajad
By Trading Economics
Sissetulek	-4.1M 45M
Müük	-25M 114M
P/E Sektori keskmine	12.868 62.58
Aktsiakasum	0.17
Kasumimarginaal	39.59
Töötajad	640
EBITDA	-4.2M 61M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+123.06% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-367M 2B
Eelmine avamishind	9.34
Eelmine sulgemishind	8.26

Uudiste sentiment

By Acuity

91%

320 / 340 Pingereas Healthcare

ADMA Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22. juuli 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21. juuli 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20. juuli 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Võrdlus sarnastega

Hinnamuutus

ADMA Biologics Inc Prognoos

Hinnasiht

By TipRanks

123.06% tõus

12 kuu keskmine prognoos

Keskmine 18.67 USD 123.06%

Kõrge 21 USD

Madal 17 USD

Põhineb 3 Wall Streeti analüütiku instrumendi ADMA Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi ADMA Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

320 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.